Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a wistar rat model

Toxicological Sciences

Volumn 46, Issue 2, 1998, Pages 342-351

  Holmes, J ^a   Stanko, J ^a   Varchenko, M ^a   Hong, H ^a   Madden, V J ^a   Bagnell, C R ^a   Wyrick, S D ^a   Chaney, S G ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; OXALIPLATIN; TETRAPLATIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG RETENTION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MASS SPECTROMETRY; MORPHOMETRICS; NEUROTOXICITY; NONHUMAN; RAT; SPINAL GANGLION;

ANIMALIA; RATTUS NORVEGICUS;

EID: 0032433642     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1006/toxs.1998.2558     Document Type: Article

References (36)

1. F. Bertheault-Cvitkovic A. Jami M. Ithzaki P.D. Brummer S. Brienza R. Adam F. Kunstlinger H. Bismuth J.L. Misset F. Levi Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer J. Clin. Oncol. 14 1996 2950 2958
2. K.S. Blisard D.A. Harrington D.A. Long J.E. Jackson Relative lack of toxicity of transplatin compared with cisplatin in rodents J. Comp. Pathol. 105 1991 367 375
3. S. Cascinu L. Cordella E. Delferro M. Fronzoni G. Catalano Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A randomized double-blind placebo-controlled trial J. Clin. Oncol. 13 1995 26 32
4. G. Cavaletti M.G. Petruccioli G. Tredici P. Marmiroli I. Barajon D. Fabbrica A. Di Francesco Effects of repeated administration of low doses of cisplatin on the rat nervous system Int. J. Tissue React. 13 1991 151 157
5. G. Cavaletti G. Tredici P. Marmiroli M.G. Petruccioli I. Barajon D. Fabbrica Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats Acta Neuropathol. 84 1992 364 371
6. P. Chollet M.A. Bensmaine S. Brienza C. Deloche H. Cure H. Caillet E. Cvitkovic Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer Ann. Oncol. 7 1996 1065 1070
7. A. de Gramont J. Vignoud C. Tournigand C. Louvet T. Andre C. Varette E. Raymond S. Moreau N. Le Bail M. Krulik Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48 hour continuous infusion in pretreated metastatic colorectal cancer Eur. J. Cancer 33 1997 214 219
8. J.M. Extra M. Espie F. Calvo C. Ferme L. Mignot M. Marty Phase I study of oxaliplatin in patients with advanced cancer Cancer Chemother. Pharmacol. 25 1990 299 303
9. W.Q. Gao N. Dybdal N. Shinsky A. Murnane C. Schmelzer M. Siegel G. Keller F. Hefti H.S. Phillips J.W. Winslow Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy Ann. Neurol. 38 1995 30 37
10. R.W. Gregg J.M. Molepo V.J.A. Monpetit N.Z. Mikael D. Redmond M. Gadia D.J. Stewart Cisplatin neurotoxicity: The relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity J. Clin. Oncol. 10 1992 795 803
11. F.P.T. Hamers R.G. van der Hoop P.A. Steerenburg J.P. Neijt W.H. Gispen Putative neurotrophic factors in the protection of cisplatin-induced peripheral neuropathy in rats Toxicol. Appl. Pharmacol. 111 1991 514 522
12. F.P.T. Hamers J.H. Brakkee E. Cavalletti M. Tedeschi L. Marmonti G. Pezzoni J.P. Neijt W.H. Gispen Reduced glutathione protects against cisplatin-induced neurotoxicity in rats Cancer Res. 53 1993 544 549
13. F. Levi J.-L. Misset S. Brienza R. Adam G. Metzger M. Itzhaki J.-P. Caussanel F. Kunstlinger S. Lecouturier A. Descorps-Declere C. Jasmin H. Bismuth A. Reinberg A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump: High antitumor effectiveness against metastatic colorectal cancer Cancer 69 1992 893 900
14. F. Levi B. Perpoint C. Garufi C. Focan P. Chollet P. Depres-Brummer R. Zidani S. Brienza M. Itzhaki S. Iacobelli F. Kunstlinger J. Gastiaburu J.-L. Misset Oxaliplatin activity against metastatic colorectal cancer—A phase-II study of 5-day continuous venous infusion at circadian rhythm modulated rate Eur. J. Cancer 29A 1993 1280 1284
15. F.A. Levi R. Zidani J.-M. Vannetzel B. Perpoint C. Focan R. Faggiuolo P. Chollet C. Garufi M. Itzhaki L. Dogliotti S. Iacobelli R. Adam F. Kunstlinger J. Gastiaburu H. Bismuth C. Jasmin J.-L. Misset Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial J. Natl. Cancer Inst. 86 1994 1608 1617
16. F. Levi R. Zidani J.-L. Misset Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer Lancet 350 1997 681 686
17. G. Los P.H.A. Mutsaers W.J.F. van der Vijgh G.S. Baldew P.W. de Graaf J.G. McVie Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: A comparison with systemic chemotherapy Cancer Res. 49 1989 3380 3384
18. D. Machover E. Diaz-Rubio A. de Gramont A. Schilf J.-J. Gastiaburu S. Brienza M. Itzhaki G. Metzger D. N'Daw J. Vignoud A. Abad E. Francois E. Gamelin M. Marty J. Sastre J.-F. Seitz M. Ychou Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines Ann. Oncol. 7 1996 95 98
19. G. Mathe Y. Kidani M. Noji R. Maral C. Bourut E. Chenu Antitumor activity of l Cancer Lett. 27 1985 135 143
20. M.J. McKeage F.E. Boxall M. Jones K.R. Harrap Lack of neurotoxicity of oral bisacetatoamminedichlorocyclohexylamineplatinum(IV) in comparison to cisplatin and tetraplatin in the rat Cancer Res. 54 1994 629 631
21. J.L. Misset Y. Kidani J. Gastiaburu C. Jasmin F. Levi N. Boughattas G. Lemaigre J.P. Caussanel B.K. Triana E. Goldschmidt M. Musset R.Y. Mauvernay G. Mathe Oxalatoplatinum (1-OHP): Experimental and clinical studies Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 1991 Plenum Press New York p. 369–375
22. J.E. Mollman D.J. Glover W.M. Hogan R.E. Furman Cisplatin neuropathy: Risk factors, prognosis, and protection by WR-2721 Cancer 61 1988 2192 2195
23. J.E. Mollman Cisplatin neurotoxicity N. Engl. J. Med. 322 1990 126 127
24. L.J. Muller R.G. van der Hoop C.M. Moorer-van Delft W.H. Gispen E.W. Roubos Morphological and electrophysiological study of the effects of cisplatin and ORG 2766 on rat spinal ganglion neurons Cancer Res. 50 1990 2347 2442
25. P. New R. Barohn T. O'Rourke J. Seharaseyan J.R. Mendell Z. Sahenk Neuropathy following ormaplatin administration: Human and laboratory studies Proc. ASCO 12 1993 155
26. T.J. O'Rourke G.R. Weiss P. New H.A. Burris G. Rodriguez J. Eckhardt J. Hardy J.G. Kuhn S. Fields G.M. Clark D.D. Von Hoff Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812) Anti-Cancer Drugs 5 1994 520 526
27. R.J. Schilder F.P. LaCreta R.P. Perez S.W. Johnson J.M. Brennan A. Rogatko S. Nash C. McAleer T.C. Hamilton D. Roby R.C. Young R.F. Ozols P.J. O'Dwyer Phase-I and pharmacokinetic study of ormaplatin (tetraplatin, NSC-363812) administered on a day-1 and day- 8 schedule Cancer Res. 54 1994 709 717
28. D. Screnci H.M. Er T.W. Hambley P. Galettis W. Brouwer M.J. McKeage Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin Br. J. Cancer 76 1997 502 510
29. K. Tomiwa C. Nolan J.B. Cavanagh The effects of cisplatin on rat spinal ganglia: A study by light and electron microscopy and by morphometry Acta Neuropathol. 69 1986 295 308
30. G. Tredici G. Cavaletti M.G. Petruccioli D. Fabbrica M. Tedeschi P. Venturino Low-dose glutathione administration in the prevention of cisplatin-induced peripheral neuropathy in rats Neurotoxicology 15 1994 701 704
31. R.G. van der Hoop P. De Koning E. Boven J.P. Neijt F.G.I. Jennekens W.H. Gispen Efficacy of the neuropeptide ORG 2766 in the prevention and treatment of cisplatin-induced neurotoxicity in rats Eur. J. Cancer Clin. Oncol. 24 1988 637 642
32. R.G. van der Hoop C.J. Vecht M.E.L. van der Burg A. Elderson W. Boogerd J.J. Heimans E.P. Vries J.C. van Houwelingen F.G.I. Jennekens W.H. Gispen J.P. Neijt Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer N. Engl. J. Med. 322 1990 89 94
33. R.G. van der Hoop F.P.T. Hamers J.P. Neijt H. Veldman W.H. Gispen F.G.I. Jennekens Protection against cisplatin induced neurotoxicity by ORG 2766: Histological and electrophysiological evidence J. Neurol. Sci. 126 1994 109 115
34. L.R. Whitefied D.G. Pegg Toxicokinetics of anticancer compounds P.G. Welling F.A. de la Inglesia Drug Toxicokinetics 1993 Dekker New York 267 289
35. S.D. Wyrick S.G. Chaney Tritiated platinum antitumor agents containing the trans-( d l J. Label. Comp. Radiopharm. 25 1987 349 357
36. S.D. Wyrick S.G. Chaney Synthesis of [195mPt]-tetraplatin J. Label. Comp. Radiopharm. 28 1990 753 756